Zacks Research Analysts Lift Earnings Estimates for Azitra

Azitra, Inc. (NYSEAMERICAN:AZTR) – Equities researchers at Zacks Research increased their FY2026 earnings estimates for Azitra in a research report issued to clients and investors on Friday, May 22nd. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings of ($0.25) per share for the year, up from their prior forecast of ($0.71). The consensus estimate for Azitra’s current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Azitra’s FY2027 earnings at ($0.08) EPS.

Azitra Trading Down 1.6%

Shares of AZTR stock opened at $0.21 on Thursday. The company has a 50 day moving average price of $0.22 and a 200-day moving average price of $0.26. Azitra has a 52 week low of $0.10 and a 52 week high of $2.40.

Azitra (NYSEAMERICAN:AZTR) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.24).

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.